Short Interest in Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Drops By 66.7%

Key Points

• Short Interest Decrease: Orion OYJ Unsponsored ADR has seen a significant decrease in short interest, dropping by 66.7% from 300 shares to just 100 shares as of July 15th.
• Earnings Report: The company reported earnings of $0.33 per share and revenue of $472.57 million for the quarter ending July 18th, with a net margin of 22.61%.
• Stock Performance: As of recent trading sessions, Orion OYJ's stock price reached $40.42, with a market capitalization of $11.41 billion and a P/E ratio of 27.49.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 100 shares, adropof66.7% from the June 30th total of 300 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 0.5 days. Currently,0.0% of the company's shares are sold short. Currently,0.0% of the company's shares are sold short. Based on an average trading volume of 200 shares, the short-interest ratio is currently 0.5 days.

Orion OYJ Trading Up 0.3%

Shares of OTCMKTS:ORINY traded up $0.12 during midday trading on Friday, reaching $40.80. The company's stock had a trading volume of 254 shares, compared to its average volume of 517. Orion OYJ has a fifty-two week low of $21.70 and a fifty-two week high of $41.60. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.27 and a current ratio of 1.86. The firm has a 50 day moving average price of $37.38 and a two-hundred day moving average price of $31.68. The firm has a market capitalization of $11.52 billion, a price-to-earnings ratio of 27.76 and a beta of 0.10.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last issued its quarterly earnings results on Friday, July 18th. The company reported $0.33 earnings per share (EPS) for the quarter. The firm had revenue of $472.57 million for the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. As a group, analysts forecast that Orion OYJ will post 1.18 earnings per share for the current year.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.